Erlotinib
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8728 publications
Harnessing Box-Behnken design to optimize erlotinib-niclosamide co-loaded liposomes, overcoming EGFR-mutated lung cancer resistance, and improving sensitivity via EGFR/STAT3 signaling pathway.
Journal: Journal of liposome research
Published: June 22, 2026
Integrating Metronomic Therapy With Standard Chemotherapy in Advanced Unresectable Head and Neck Cancer: A Randomized Trial Addressing Global Cancer Care Equity (METRO PLUS).
Journal: JCO global oncology
Published: June 17, 2026
EGFR INHIBITION PROMOTES ENTEROENDOCRINE CELL DIFFERENTIATION CONTRIBUTING TO TREATMENT-ASSOCIATED DIARRHEA.
Journal: bioRxiv : the preprint server for biology
Published: June 12, 2026
Structure-Based Design and Optimization of Novel PHGDH Inhibitors for Overcoming Erlotinib-Resistant Lung Cancer.
Journal: Journal of medicinal chemistry
Published: June 09, 2026
Design and Pictet-Spengler enabled synthesis of carboxamide-substituted imidazo[1,2-a]quinoxalines as dual EGFR and tubulin targeting anticancer agents.
Journal: Journal of enzyme inhibition and medicinal chemistry
Published: May 25, 2026
Response to Third-Line Erlotinib in Peritoneal Carcinomatosis from Initially EGFR Mutation-Negative Lung Adenocarcinoma, Followed by the Retrospective Confirmation of EGFR Mutation-Positivity by Immunohistochemistry.
Journal: Internal medicine (Tokyo, Japan)
Published: May 24, 2026
Osimertinib rechallenge using an oral anti-urticarial medication regimen following full body Urticaria: A case report.
Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: May 13, 2026
An In silico model-based feasibility assessment of erlotinib long-acting injectable formulation for the management of metastatic non-small cell lung cancer.
Journal: Xenobiotica; the fate of foreign compounds in biological systems
Published: April 22, 2026
Novel pyrimidine-triazole conjugates for targeted inhibition of EGFR: synthesis and biological evaluation.
Journal: Future medicinal chemistry
Published: April 16, 2026
Hypoxia-activated PROTAC for dual inhibition of FAK and EGFR enables synergistic mechano-chemical cancer therapy.
Journal: Neoplasia (New York, N.Y.)
Published: April 09, 2026
Multi-omics analysis identified SPRR2D as a potential biomarker for tumor prognosis and immune microenvironment infiltration: a pan-cancer perspective.
Journal: Future science OA
Published: April 04, 2026
Last Updated: 06/30/2026